UK markets closed

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
395.92+4.45 (+1.14%)
At close: 12:57PM EST

Genmab A/S

Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
http://www.genmab.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,136

Key executives

NameTitlePayExercisedYear born
Dr. Jan G.J. van de WinkelCo-Founder, Pres & CEO2.67MN/A1961
Mr. Anthony PaganoExec. VP & CFO904.38kN/A1978
Mr. Anthony ManciniExec. VP & COO1.37MN/A1971
Mr. Peter Storm KristensenDirector of Legal Lead Corp. & Non-Independent Director60.29kN/A1975
Dr. Judith V. KlimovskyExec. VP & Chief Devel. Officer1.09MN/A1958
Dr. Mijke Zachariasse Ph.D.Director of Protein Production & Chemist and Non-Independent Director60.29kN/A1974
Dr. Rima Bawarshi Nassar Ph.D.VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director15.07kN/A1953
Mr. Peter RosSr. Director of Fin. & AccountingN/AN/AN/A
Mr. Andrew CarlsenSr. Director & Head of Investor RelationsN/AN/AN/A
Ms. Birgitte Stephensen M.Sc.Sr. VP & Head of Global IPR and LegalN/AN/A1961
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Corporate governance

Genmab A/S’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.